AngioDynamics (NASDAQ:ANGO) Shares Down 7.1% – What’s Next?

Posted by Francis Steltz on Oct 6th, 2026

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) shares dropped 7.1% during trading on Tuesday. The company traded as low as $14.51 and last traded at $14.4350. Approximately 272,285 shares changed hands during trading, a decline of 43% from the average session volume of 478,868 shares. The stock had previously closed at $15.54.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ANGO shares. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Finally, Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $19.50.

Check Out Our Latest Stock Report on ANGO

AngioDynamics Trading Down 7.2%

The stock has a 50-day simple moving average of $15.47 and a 200-day simple moving average of $13.06. The company has a market capitalization of $606.66 million, a price-to-earnings ratio of -16.60 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last released its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, research analysts forecast that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 6.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently made changes to their positions in ANGO. Integrated Wealth Concepts LLC acquired a new position in AngioDynamics in the 2nd quarter valued at approximately $38,000. Legal & General Group Plc bought a new stake in AngioDynamics during the 2nd quarter valued at approximately $45,000. Public Employees Retirement System of Ohio bought a new stake in AngioDynamics in the 2nd quarter valued at $64,000. State of Wyoming acquired a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $72,000. Finally, Inceptionr LLC bought a new stake in shares of AngioDynamics in the 1st quarter valued at approximately $115,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.